Patents for A61P 35 - Antineoplastic agents (221,099)
03/2004
03/18/2004WO2004022028A1 Composition containing feverfew extract and use thereof
03/18/2004WO2004021996A2 Backbone-substituted bifunctional dota ligands, complexes and compositions thereof, and methods of using same
03/18/2004WO2004021995A2 Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
03/18/2004WO2004021977A2 Nucleic acid and corresponding protein entitled 98p4b6 useful in treatment and detection of cancer
03/18/2004WO2004012733A3 Compounds useful for the treatment of diseases responsive to antiangiogenetic therapy
03/18/2004WO2004009596A3 Pyrazolopyrimidines as kinase inhibitors
03/18/2004WO2004002482A3 2-pyridin acetic acid derivatives with antiproliferative activity
03/18/2004WO2004000204A8 Labelled somatostatin analogs backbone cyclized through metal complexation
03/18/2004WO2003099289A3 Compositions and their uses for alleviating pain
03/18/2004WO2003099192A3 Bis-aromatic alkanols
03/18/2004WO2003097608A3 Opioid and opioid-like compounds and uses thereof
03/18/2004WO2003092719A3 Methods and compositions for modulating beta-catenin phosphorylation
03/18/2004WO2003092623A3 Calicheamicin derivative-carrier conjugates
03/18/2004WO2003084936A3 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
03/18/2004WO2003076461A3 Dimeric tf antagonist comprising two factor vii polypeptides
03/18/2004WO2003072603A3 Long pentraxin ptx3 functional derivatives for preparing an autologous vaccine for the treatment of tumours
03/18/2004WO2003070965A3 The eaat2 promoter and uses thereof
03/18/2004WO2003070750A3 Rna interference mediated inhibition of hepatitis c virus
03/18/2004WO2003066904A3 Methods for determining the response of cells to vegf and uses thereof
03/18/2004WO2003054197A3 A library of modified structural genes or capsid modified particles useful for the identification of viral clones with desired cell tropism
03/18/2004WO2003044172B1 Composition comprising and method of using angiopoietin-like protein 3 angptl3
03/18/2004WO2003039434A3 Process of preparation of formulations of the peptide angiotensin-(1-7) and its analogues, agonistic and antagonists using cyclodextrins, lipossomes and biodegradable polymers and/or mixtures and products thereof
03/18/2004WO2003035688A3 Targeted thrombosis by tissue factor polypeptides
03/18/2004WO2003035009A3 Treatment of acute myeloid leukemia with indolinone compounds
03/18/2004WO2003032813A3 Methods for the treatment of carcinoma
03/18/2004WO2003028630A3 Methods and compositions for modulating interleukin-21 receptor activity
03/18/2004WO2003026563A3 Conjugated anti-psychotic drugs and uses thereof
03/18/2004WO2003022202A3 Compositions and methods for treatment of cancer
03/18/2004WO2003007874A3 Anti-tumor activity from reptile serum
03/18/2004WO2003007869A3 Immunogenic compositions containing antigens, gene vectors and adjuvants-loaded biodegradable microspheres
03/18/2004WO2003007800A8 Methods for diagnosing and treating diseases and conditions of the digestive system and cancer
03/18/2004WO2002102972A3 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
03/18/2004WO2002095034A9 A retinoic acid metabolizing cytochrome p450
03/18/2004WO2002080856A3 Triaza compound immunoregulatory agents
03/18/2004WO2002060867A3 Carbazole derivatives and their uses as heparanase inhibitors
03/18/2004US20040054212 Combretastatin A-4 phosphate prodrug mono-and di-organic amine salts, mono-and di-amino acid salts, and mono-and di-amino acid ester salts
03/18/2004US20040054190 Imaging prostate cancer
03/18/2004US20040054188 Desorption; reverse phase chromatography
03/18/2004US20040054186 Autoimmune diseases; anticancer agents; antiproliferative agents; skin disorders
03/18/2004US20040054180 Kinase inhibitors; antiinflammatory agents; respiratory system disorders; cardiovascular disorders; antidiabetic agents
03/18/2004US20040054179 Antiallergens; skin disorders; antitumor agents; tyrosine kinase inhibitor
03/18/2004US20040054172 Oxygenated esters of 4-lodo phenylamino benzhydroxamic acids
03/18/2004US20040054158 GL50 molecules and uses therefor
03/18/2004US20040054155 Oligonucleotide compositions with enhanced efficiency
03/18/2004US20040054149 Modified proteolytic enzyme for treatment of osteoarthritis
03/18/2004US20040054145 Truncated cd200
03/18/2004US20040054143 Vegf peptides and their use for inhibiting angiogenesis
03/18/2004US20040054142 Cripto tumour polypeptide
03/18/2004US20040054137 Chimeric protein for diagnosis and treatment of cancers and infections; immunotherapy
03/18/2004US20040054136 Comprises nucleotide sequences coding transporter associated with antigen processing-like polypeptides (human TAP-like) for diagnosis and treatment of infection, tumors and autoimmune diseases
03/18/2004US20040054014 Administering to subject at least one chemotherapeutic agent and at least one 3-aryloxy-3-phenylpropylamine; for multidrug resistance cancer
03/18/2004US20040054001 For preparing a pharmaceutical composition for treating diseases that may be influenced by NF-kappaB, particularly psoriasis
03/18/2004US20040053998 For treating restenosis in tissue wherein smooth muscle cell migration occurs following angioplasty; for treatment of chronic inflammation, ischemic diseases and cancer
03/18/2004US20040053987 Bis-heterocyclic compounds with antitumour and chemosensitising activity
03/18/2004US20040053983 1, 2, 4-tribsubstituted benzenes as inhibitors of 15-lipoxygenase
03/18/2004US20040053982 Such as 3-(2-(6-methyl-pyridin-2-ylamino)-5-(1,2,4)triazol-1-yl-thiazol-4 -yl)benzonitrile for treatment of inflammatory or obstrucive airways diseases
03/18/2004US20040053981 Such as 2-(5(6)-nitro-2-benzimidazoyl)-5-(4-nitrophenyl)furan; fluorescent quantitative analysis; for treatment/prevention of cancer
03/18/2004US20040053972 Medicinal compositions having improved absorbability
03/18/2004US20040053960 Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors
03/18/2004US20040053958 Di and trifluoro-triazolo-pyridines anti-inflammatory compounds
03/18/2004US20040053957 Enzyme inhibitors of the I kappa B kinase, therapeutic treatment of autoimmune diseases, inflammatory diseases and cancer; chemical intermediates, sulfiding, sulfonation, desulfonation, cyclization
03/18/2004US20040053955 An immunosuppressants for treating allograft rejection, transplant rejection, psoriasis, and rheumatoid arthritis, a 9,10-dihydro-9-oxo-acridine-3-yl- derivatives
03/18/2004US20040053953 Treatment of chemokine mediated diseases
03/18/2004US20040053951 Non-peptide GnRH agents, pharmaceutical compositions, and methods for their use
03/18/2004US20040053947 Pyrrolo[2,3-D]pyrimidine compounds
03/18/2004US20040053946 Cancer treatment method
03/18/2004US20040053944 Antiprotozoa agents; 4-pyrrolidine pyrrolo(3,2-d)pyrimidine and 4-pyrrolidine pyrazolo(4,3-d)pyrimidine derivatives
03/18/2004US20040053943 Novel compounds
03/18/2004US20040053942 Fused pyrazole derivatives bieng protein kinase inhibitors
03/18/2004US20040053941 Substituted pyrazine derivatives
03/18/2004US20040053935 Anticancer agents
03/18/2004US20040053934 Anticancer agents
03/18/2004US20040053931 Kinase inhibitors; angiogenesis inhibitors, anticancer agents, antiinflammatory agents and chronic obstructive pulmonary disease inhibitors
03/18/2004US20040053925 Novel urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use
03/18/2004US20040053924 Reacting pyrrolo(2,3-d)pyrimidin-4-one derivative containing a leaving group with a aromatic or heteroaromatic amine, hydroxy, marcaptan etc. in presence of a polar solvent and a catalyst
03/18/2004US20040053922 Metabolites of prinomastat and their synthesis
03/18/2004US20040053920 Administering to a patient suffering from caspase mediated diseses, an effective amount of a mono,bi or tri-heterocyclic ring containing nitrogen atom attached to ester or thioester to form carbamate group, as caspase inhibitor
03/18/2004US20040053917 Reacting cyanophenyl-4-sulfonylchloride with a piperidine-4-oxo in presence of ethylene glycol to form an intermediate, reducing cyano group, followed by amidation, then reacting with an amine to form sulfonamide end
03/18/2004US20040053909 Administering to a cancer patient a geldanamycin derivative containing dimethylaminoethylamine (at 17the position) group attached to the ring, for the treatment of cancer
03/18/2004US20040053908 Urea derivatives containing aromatic or heteroaromatic rings, useful as prophylactic or therapeutic agent for a disease for which angiogenesis inhibition is effective
03/18/2004US20040053900 Administering to a mammal a combination of cyclooxygenase-2 inhibitor and aromatase inhibitor for the prevention, or inhibition of a neoplasia, a neoplasia-related disorder, or osteoporosis in mammal in need
03/18/2004US20040053896 Pharmaceutically active compound
03/18/2004US20040053883 Crystalline forms of pyrimidine nucleoside derivative
03/18/2004US20040053882 Comprises sterically hindered platinum coordination compound such as (SP-4-3)-(cis-aminedichloro-(2-methylpyridine)platinum complex, non- platinum based anticancer agent (taxol), and carrier; kits
03/18/2004US20040053875 Comprises double-stranded RNA; extracted from HeLa cells
03/18/2004US20040053874 Polynucleotide that hybridize with and inhibit gene expression for amphipathic dimeric glycoproteins
03/18/2004US20040053873 Electroporation methods for introducing bioactive agents into cells
03/18/2004US20040053872 Administering polynucletides that inhibit interactions polymerases with tRNA, to humans for prophylaxis of aquired immune deficiency syndrome
03/18/2004US20040053863 Sensitization of HER-2/neu overexpressing cancer cells to chemotherapy
03/18/2004US20040053851 Association of calpain inhibitors and reactive oxygen species trapping agents
03/18/2004US20040053847 Suitable for treatment of cancer and for treatment, particularly topical treatment, of infections caused by pathogenic organisms such as bacteria and fungi
03/18/2004US20040053845 Modified peptides as therapeutic agents
03/18/2004US20040053842 Cholesterol ester transfer protein inhibitors for use in treating atherosclerosis optionally in combination with other antihypertensive agents
03/18/2004US20040053833 Relates to regulation of activity of NET (ERP/SAP-2) protein and to compounds which modify or regulate NET protein activity; methods of screening for agonists or antagonists of NET in order to identify new pro- or anti-angiogenic compounds
03/18/2004US20040053829 Polypeptide having preferably antitumoral and/or immunomodulating cytokine properties, which can be activated by processing in vivo comprising a central region with specific biological activity
03/18/2004US20040053828 Partial peptide mimetics and methods
03/18/2004US20040053820 Histone deacetylase inhibitor
03/18/2004US20040053329 Endoglin-specific polypeptide, production and use thereof
03/18/2004US20040053325 Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
03/18/2004US20040053281 Comprises enzymatic polypeptide associated with fatty acid metabolism for diagnosing, treating and preventing cancer, neurodegenerative, autoimmune/inflammatory, gastrointestinal and cardiovascular disorders